Back to Search Start Over

Development of 18 F-Labeled Acridone Analogue for Tumor Imaging via Stimulator of Interferon Genes Targeting.

Authors :
Liu H
Sun Y
Li J
Chen Y
Liu J
Fang J
Yang H
Feng L
Peng S
Zhuang R
Guo Z
Zhang X
Source :
Molecular pharmaceutics [Mol Pharm] 2023 Jul 03; Vol. 20 (7), pp. 3529-3538. Date of Electronic Publication: 2023 May 27.
Publication Year :
2023

Abstract

The stimulator of interferon genes (STING) is a pivotal protein in the production of STING-dependent type I interferon, which has the potential to enhance tumor rejection. The visualization of STING in the tumor microenvironment is valuable for STING-related treatments, but few STING imaging probes have been reported to date. In this study, we developed a novel <superscript>18</superscript> F-labeled agent ([ <superscript>18</superscript> F]F-CRI1) with an acridone core structure for the positron emission tomography (PET) imaging of STING in CT26 tumors. The probe was successfully prepared with a nanomolar STING binding affinity of K <subscript>d</subscript> = 40.62 nM. [ <superscript>18</superscript> F]F-CRI1 accumulated quickly in the tumor sites and its uptake reached a maximum of 3.02 ± 0.42% ID/g after 1 h i.v. injection. The specificity of [ <superscript>18</superscript> F]F-CRI1 was confirmed both in in vitro cell uptake and in vivo PET imaging by blocking studies. Our findings suggest that [ <superscript>18</superscript> F]F-CRI1 may be a potential agent for visualizing STING in the tumor microenvironment.

Details

Language :
English
ISSN :
1543-8392
Volume :
20
Issue :
7
Database :
MEDLINE
Journal :
Molecular pharmaceutics
Publication Type :
Academic Journal
Accession number :
37243620
Full Text :
https://doi.org/10.1021/acs.molpharmaceut.3c00137